The latest price target for TherapeuticsMD (NASDAQ:TXMD) was reported by Cantor Fitzgerald on August 17, 2023. The analyst firm set a price target for $5.00 expecting TXMD to rise to within 12 months (a possible 338.60% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for TherapeuticsMD (NASDAQ:TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.

There is no last upgrade for TherapeuticsMD

The last downgrade for TherapeuticsMD Inc happened on June 7, 2022 when HC Wainwright & Co. changed their price target from N/A to $10 for TherapeuticsMD Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.

While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $1.14, which is within the analyst’s predicted range.